Innovative contracts can offer significant benefits for stakeholders delivering novel drugs and medical products to patients — but they require resources to design and implement. This Implementation Brief outlines key … Read More
Managing the challenges of paying for gene therapy: strategies for market action and policy reform in the United States
New open access policy analysis from Institute for Clinical and Economic Review (ICER) and NEWDIGS Initiative at Tufts Medical Center analyzes the challenges and potential policy options for paying for … Read More
Implementation Brief: Innovative contracting 101
This brief provides an introduction to innovative contracts, or value-based contracts, which may be used to facilitate access to innovative, high-cost treatments. These contracts can address uncertainty around treatments and … Read More
Implementation Brief: Access considerations for innovative treatments
This brief offers a checklist of key steps that different stakeholders should consider to ensure patients have access to innovative treatments. These therapies present unique challenges for different stakeholders and … Read More
NEWDIGS leaders named to Illinois SCD Advisory Council
Our Strategic Director Mark Trusheim was appointed by Illinois Governor Pritzker to the Advisory Council on Financing and Access to Sickle Cell Disease Treatment and Other High-Cost Drugs & Treatment. Rena … Read More
Implementation Brief: Key terms for payment innovation
This brief provides definitions of key terms that are often used in discussions about designing and implementing innovative payment solutions. It offers an overview of solution models, types of risk, … Read More
ISPOR 2024 panel recap: Will the Pediatric Rare Disease Pipeline Create a Financial Tsunami? Implications of a Monte Carlo Projection
Atlanta, GA – On Monday, May 6, NEWDIGS community members presented a panel discussion at the annual ISPOR meeting, “Will the Pediatric Rare Disease Pipeline Create a Financial Tsunami? Implications of … Read More
Implementation Brief: Considerations for developers in applying the Multiple Best Price (MBP) rule to improve access to novel therapies
This brief highlights some key steps and considerations for biopharmaceutical developers of novel, high-value therapies seeking to successfully implement CMS’s Multiple Best Price rule. The rule, which went into effect … Read More
Implementation Brief: Understanding access issues for new therapies
Our first implementation brief outlines several major barriers to patient access for novel cell and gene therapies. It also describes how providers, payers, and developers may overcome these barriers, with … Read More
Managing the Challenges of Paying for Gene Therapy: Strategies for Market Action and Policy Reform
Gene therapies delivered through a single administration have revolutionized treatment possibilities for many patients living with serious or fatal conditions such as spinal muscular atrophy, hemophilia, and sickle cell disease. … Read More